Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 20, 2025Open Access

Supplementary Figure S3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSamantha I. LiangParker Institute for Cancer ImmunotherapyZQZoe QuandtUniversity of California, San FranciscoSWSara WienkeGuardant (United States)

Discussion

Loading...

Member takes

Implication

Supplementary analysis predicts clinical outcomes in patients undergoing treatment with immune checkpoint inhibitors, indicating tumor fraction changes are crucial.

Key Points

  • Tumor fraction changes are predictive of long-term clinical benefit from immune checkpoint inhibitors, enhancing prognosis.
  • Baseline tumor fraction detection shows prognostic value, with significant outcome implications for patients.
  • The analysis utilizes a real-world cancer study framework, assessing broad impacts across various cancer types.
  • Identifying tumor fraction changes may enable better-targeted therapies and improve patient management strategies.

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/68af750c7567bf4f94feddd9https://doi.org/10.1158/2767-9764.29948090
View Full Paper
Ask AI
Bookmark
Share